The study is designed as a prospective, multi-center, open-label, ,randomized, placebo-controlled study in 5 tertiary academic medical centers which are medical, surgical or general ICUs. Patient enrollment is expected to last up to 42 months. They will be randomly assigned in a 1:1 ratio into two groups. Both groups receive appropriate medical support and treatment based on guidelines issued by the surviving sepsis campaign.